Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Englewood, New Jersey Clinical Trials

A listing of Englewood, New Jersey clinical trials actively recruiting patient volunteers.

Found (241) clinical trials

MCLA-117 in Acute Myelogenous Leukemia

Study Design : This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1 consists of dose escalation cohorts and Part 2 is a dose expansion cohort. The study population will include adult AML patients (and all subtypes of AML) with relapse or refractory disease and newly …

Phase

7.28 miles

Learn More »

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

This is a single arm, proof-of-concept study. Fifteen subjects with urothelial cancer interested in participation will sign a "tissue acquisition and vaccine preparation consent" after which tumor tissue will be obtained from either a surgical resection specimen or biopsy. Subjects are scheduled to undergo cystectomy or nephroureterectomy for invasive urothelial …

Phase

7.28 miles

Learn More »

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 will be administered as an intravenous infusion once every four weeks. The study consists of two segments: dose escalation (DES) …

Phase

7.28 miles

Learn More »

A Study of ASP1948 Targeting an Immune Modulatory Receptor in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1948 as a single agent and in combination with nivolumab or pembrolizumab. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will …

Phase

7.28 miles

Learn More »

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

This is an open label, non-randomized Phase I study of intravenous avelumab every 2 weeks to be administered after real-time MRI-guided LITT therapy for patients with a first recurrence of a glioblastoma. The primary objective of the study is to characterize the tolerability and safety profile of avelumab in combination …

Phase

7.28 miles

Learn More »

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of multiple immunotherapy combinations in participants with mCRPC who have received prior therapy. The platform study will consist of 2 stages: Stage 1, an initial stage to evaluate safety, biomarkers, and clinical activity of …

Phase

7.28 miles

Learn More »

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

All subjects who received investigational CAR-T therapy will be included in the analyses and summaries of safety, efficacy, pharmacokinetic, and pharmacodynamic assessments.

Phase

7.28 miles

Learn More »

Selinexor Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the combination of selinexor, carfilzomib, and dexamethasone in relapsed and relapsed/refractory multiple myeloma. SECONDARY OBJECTIVES: I. Determine safety and tolerability. II. Determine the efficacy, as measured by the rates of stable disease or …

Phase

7.28 miles

Learn More »

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

This is a single-arm, single institution phase 1a / 1b study to test the safety, tolerability, and immunogenicity of MTA-based personalized vaccine in patients with newly diagnosed GBM along with the use of continual TTFields. MTA-based personalized vaccine is prepared in the laboratory with several peptides based on each patient's …

Phase

7.28 miles

Learn More »

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, status or response. The …

Phase

7.28 miles

Learn More »